Global Survey 2020 Results: Self-Treatment of LSD and Psilocybin

The Global Drug Survey 2020 is a large online survey on drug use collected between November 2019 and February 2020.

Positive changes were observed across all 17 outcome items, with the strongest benefits on items related to insight and mood. Negative effects were reported by 22.5% of respondents.

High intensity of psychedelic experience, seeking advice before treatment, treating with psilocybin mushrooms and treating post-traumatic stress disorder were associated with higher scores on the self-treatment outcome scale after averaging values across all 17 items.

Younger age, high intensity of experience and treating with LSD were associated with increased number of negative outcomes.

Read more

A Non-Hallucinogenic LSD Analog?

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, announced that findings from a study on its lead candidate BETR-001 (2-bromo-LSD) titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders” has been published in the peer-reviewed journal of Cell Report.

What do you think?

Read more

New Research on the Brain and Serotonin

The more we study psychedelics and related drugs, the more we learn about how the brain functions and how to better repair it when it goes haywire.

A new study published in the journal Science illuminates the relationship between changes in the brain and serotonin using psychedelics in mice to show how different cells react.

These reactions are what seems to create changes in the brain that improve mental health.

Read more